WTX-124
- Indication
- Solid Tumors
- Stage
- phase1
- Event
- Conference Presentation
- Details
Oct. 30, 2026: Werewolf Therapeutics (NASDAQ: HOWL) announced upcoming SITC 2026 presentations on its cancer immunotherapy programs. An oral presentation will cover a Phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124, given alone or with pembrolizumab, in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors. The abstract is #1189, to be presented by Justin Moser, M.D., on November 7, 2026, from 2:30-2:45 p.m. MT in Phoenix.
The company will also present a poster on WTX-330, a tumor-activated IL-12 prodrug, from a Phase 1b/2 study in patients with relapsed/refractory solid tumors. The poster abstract is #494 and will be available November 7, 2026, from 9 a.m.-8:30 p.m. MT.
The catalyst is a conference data presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026. No clinical results were disclosed in the provided content.
- Source
- View catalyst source ↗